The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background & Aims
Severe cutaneous adverse drug reactions (SCARs) including Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP) are high‐mortality adverse drug reactions. The risk factors and prognosis of drug‐induced liver injury (DILI) concomitant with SCAR warrant...
Background: In the GLOBE trial, telbivudine demonstrated superior efficacy to lamivudine at 2 years in patients with chronic hepatitis B (CHB).
Aims: To investigate the long‐term efficacy and safety of telbivudine in the telbivudine‐treated cohort from the GLOBE trial.
Methods: Virological and biochemical responses were assessed in 213 HBeAg‐positive and 186 HBeAg‐negative CHB patients who continued...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.